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Abstract
Because the liver is central in the maintenance of glucose homeostasis and energy storage, knowledge of the physiology as well as
physiopathology of hepatic energy metabolism is a prerequisite to our understanding of whole body metabolism. Hepatic fuel
metabolism changes considerably depending on physiological circumstances (fed fasted state). In consequence, hepaticvs 
carbohydrate, lipid and protein synthesis/utilization are tightly regulated according to needs. Fatty liver and hepatic insulin
resistance (both frequently associated with the metabolic syndrome) or increased hepatic glucose production (as observed in type 2
diabetes) resulted of alterations in substrates oxidation/storage balance in the liver. Because AMPK is considered as a cellular energy
sensor, it is important to gain understanding of the mechanism by which hepatic AMPK coordinates hepatic energy metabolism.
AMPK has been implicated as a key regulator of physiological energy dynamics by limiting anabolic pathways (to prevent further
ATP consumption) and by facilitating catabolic pathways (to increase ATP generation). Activation of hepatic AMPK leads to
increased fatty acid oxidation and simultaneously inhibition of hepatic lipogenesis, cholesterol synthesis and glucose production. In
addition to a short-term effect on specific enzymes, AMPK also modulates the transcription of genes involved in lipogenesis and
mitochondrial biogenesis. The identification of AMPK targets in hepatic metabolism should be useful in developing treatments to
reverse metabolic abnormalities of type 2 diabetes and the metabolic syndrome.
MESH Keywords AMP-Activated Protein Kinases ; chemistry ; genetics ; metabolism ; Aminoimidazole Carboxamide ; analogs & derivatives ; metabolism ; Animals ; 
Dyslipidemias ; drug therapy ; metabolism ; physiopathology ; Energy Metabolism ; physiology ; Fatty Liver ; drug therapy ; metabolism ; physiopathology ; Gluconeogenesis ; 
physiology ; Glucose ; metabolism ; Homeostasis ; Humans ; Hypoglycemic Agents ; metabolism ; Lipid Metabolism ; Liver ; cytology ; enzymology ; Liver Cirrhosis ; drug
therapy ; metabolism ; physiopathology ; Mitochondria ; metabolism ; Protein Conformation ; Protein Subunits ; chemistry ; genetics ; metabolism ; Ribonucleotides ; 
metabolism
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Introduction
The ability to store nutrients is vital to survival for all organisms in periods of acute or prolonged shortage of nutrient supply. In
mammals, the liver is a major organ responsible for maintaining both short-term and long-term whole-body energy needs by its capacity to
induce a number of changes in terms of stored and released energy in the body under widely changing physiological conditions.
Alterations in energy intake induce a number of metabolic and hormonal changes in the body. The liver functions as a mediator between
dietary, as well as endogenous, sources of energy and the extrahepatic organs that continuously need energy, primarily the brain.
Metabolically, the liver is the most versatile organ of the whole body with a metabolism cycling daily between the fed and fasted states. In
the fed (anabolic) state, digestion yields simple sugars that are converted to pyruvate (via glycolysis), which is either oxidized to provide
energy or channelled into pathways for synthesis of fatty acids (via lipogenesis) for storage. Excess glucose is also stored as glycogen (the
total hepatic glucose store is only sufficient for a few hours use), providing a short-term source of carbohydrates for emergency use. The
coordinated regulation of these processes allows for efficient utilization of dietary carbohydrate. Hepatic fuel metabolism changes
considerably under the different nutritional situations. In the fasted (catabolic) state, the liver becomes a glucose producer (breakdown of
stored hepatic glycogen and synthesis of glucose from lactate, amino acids, glycerol, and pyruvate), lipogenesis is slowed down, and fatty
acid oxidation and ketogenesis are activated to supply energy and metabolic fuels for extrahepatic organs. Because the liver is the
metabolic factory of the body, alterations in liver function clearly affect whole-body metabolism and energy homeostasis and underlie the
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development of metabolic diseases, including type 2 diabetes and the metabolic syndrome. Hence, understanding the mechanisms
regulating hepatic energy metabolism is a prerequisite for developing new pharmacological strategies aimed at treating these metabolic
diseases.
Over the last few years, a growing body of evidence indicates that AMP-activated protein kinase (AMPK), a serine threonine kinase
comprising a catalytic  subunit and regulatory  and  subunits, represents a point of convergence of regulatory signals monitoringα β γ
systemic and cellular energy status. AMPK functions as a fuel sensor in most tissues and organs, including liver, skeletal muscle, heart,
hypothalamus and adipose tissue, where it inhibits anabolic pathways and stimulates catabolic pathways in response to limited energy
availability, thus simultaneously sparing limited energy resources and acquiring extra energy. AMPK acts first by directly affecting
enzymes activities, involved in carbohydrate, lipid and protein biosynthesis, and second by longer-term transcriptional control of key
players of these metabolic pathways. AMPK emerges as a major regulator of glucose and lipid metabolism and represents an attractive
target for therapeutic intervention in the treatment of hepatic disorders. Important progress has recently been made in the comprehension of
the pathophysiological role of AMPK in hepatic energy metabolism and this review provides a general overview of AMPK regulation, its
activators and its functions in the liver.
Structure and regulation of AMPK in the liver
AMPK exists as a heterotrimeric complex consisting of a catalytic subunit  and two regulatory subunits  and  involved inα β γ
heterotrimer formation and ligand sensing. The conventional serine/threonine kinase activity of AMPK is supported by the  subunit whichα
is characterized by the presence of a threonine residue within the activation loop of the kinase domain. The C-terminal region of  subunitα
is required for the association with the regulatory  and  subunits. The  subunit contains a C-terminal region acting as scaffold binding β γ β α
and  subunits and a central region that allowed AMPK complex to bind glycogen but this has been recently disputed in the liver (γ Parker et
). The  subunit contains four tandem repeats known as cystathionine -synthase (CBS) motifs which bind AMP or ATPal., 2007 γ β
molecules in a competitive manner. Recent structural studies revealed that two sites on the  subunit bind either AMP or Mg.ATP, a thirdγ
site contains a tightly bound AMP that does not exchange ( ). Isoforms of all three subunits encoding by different genes (Xiao et al., 2007 α
1, 2, 1, 2, 1, 2, 3) have been identified in mammals that allow for the generation of 12 different heterotrimeric combinations. Theseα β β γ γ γ
heterotrimeric AMPK complexes show relative tissue specificity. AMPK 1 and 2-containing complexes account each for about half ofα α
total AMPK activity in rodent liver ( ) but AMPK 1-containing complexes are predominant in human hepatocytes (B.Cheung et al., 2000 α
Guigas, unpublished results). Expression of the 1 and 1 regulatory subunits predominates in rodent liver ( ). To theβ γ Cheung et al., 2000 
best of our knowledge, no selective association between catalytic 1 and 2 and regulatory  and  subunits or differences in the activity ofα α β γ
the various hepatic AMPK complexes combination have been reported. Nevertheless, it should be noted that AMPK complexes
distribution can be regulated intracellularly with AMPK 2-containing complexes present in both nucleus and cytoplasm raising theα
possibility of direct regulation of gene transcription ( ) and with AMPK 1-containing complexes localized in the cytoplasmSalt et al., 1998 α
but also at the plasma membrane ( , ). Changes in the subcellular localization of AMPK 2 inEvans et al., 2005 Hallows et al., 2003 α
response to specific stimuli appear to be conserved from yeast to mammals via a mechanism involving the interaction with the regulatory β
subunits ( , ). In mammalian muscle cells, AMPK 2 bound to the 2 subunit translocates to theSuzuki et al., 2007 Vincent et al., 2001 α β
nucleus in a manner dependent on a nuclear localization signal that is present in AMPK 2 but not in AMPK 1 subunit. AMPK 2 bound toα α α
the 1 subunit is anchored into the cytoplasm at the outer mitochondrial membrane through the myristoylation of 1 subunit. These dataβ β
suggest that activation of AMPK complexes may elicit distinct metabolic effects in tissues and cells depending on the expression of the
different - and -subunit isoforms and illustrate the complexity of the molecular mechanisms by which energy metabolism can beα β
regulated by AMPK.
Regulation of AMPK activity involves both direct allosteric activation and reversible phosphorylation. Activation of AMPK requires
phosphorylation on Thr-172 within the catalytic subunit and three upstream kinases have been identified corresponding to the tumor
suppressor LKB1 kinase, CaMKK  (C 2 /calmodulin-dependent protein kinase kinase ) and possibly TAK1 (TGF -activated kinase-1, aβ α + β β
member of the mitogen-activated protein kinase kinase family). LKB1 is mainly involved in Thr-172 phosphorylation following change in
AMP:ATP ratio ( , , ). It has become evident in the last years that LKB1 plays aHawley et al., 2003 Shaw et al., 2004 Woods et al., 2003 
crucial role in activating AMPK to control glucose and lipid metabolism in the liver ( , ). It has beenShaw et al., 2005 Imai et al., 2006 
suggested that LKB1 may be constitutively active ( , ) but recent studies indicates that cytosolicLizcano et al., 2004 Sakamoto et al., 2004 
localization and activity of LKB1 can be governed by LKB1 acetylation status in the liver ( ). CaMKK  is viewed as anLan et al., 2008 β
alternate upstream kinase that could also phosphorylate Thr-172 and activate AMPK in intact cells by an AMP-independent manner in
response to increased intracellular Ca concentrations ( , , ). However, CaMKK2  + Hawley et al., 2005 Hurley et al., 2005 Woods et al., 2005 
 is highly expressed in neural tissue and the role for Ca -mediated AMPK activation in the liver remains to be investigated. The thirdβ 2  +
potential upstream kinase is TAK1, which activates the homologue of AMPK, the SNF1 complex, when expressed in theS. cerevisiae 
yeast ( ), and could also phosphorylate Thr-172 and activate AMPK in mouse embryonic fibroblasts (Momcilovic et al., 2006 Xie et al.,
) but its role as an upstream kinase remains controversial ( ). In addition to phosphorylation, AMPK is2006 Goransson et al., 2007 
allosterically activated by AMP which binds to the regulatory  subunit. Binding of AMP to AMPK induces a conformational change inγ
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the kinase domain that protects AMPK from dephosphorylation of Thr-172 ( ), probably catalysed by a form of proteinRiek et al., 2008 
phosphatase-2C ( ). The combination of the allosteric and phosphorylation effects causes >1000-fold increase in kinaseSanders et al., 2007 
activity ( ) allowing to respond to small changes in cellular energy status in a highly sensitive manner.Suter et al., 2006 
Activators of AMPK in the liver
AMPK is activated in response to a variety of metabolic stresses that typically, but not exclusively, change the cellular AMP:ATP
ratio, either by increasing ATP consumption (activation of biosynthetic pathways) or reducing ATP production following hypoxia, glucose
deprivation and inhibition of mitochondrial oxidative phosphorylation with metabolic poisons (arsenite, oligomycin, dinitrophenol, azide
and antimycin A) ( ). AMPK plays a central role in the metabolic adaptation to acute and chronic nutritionalTowler and Hardie, 2007 
stresses. For instance, AMPK is activated in the liver by the metabolic challenges imposed by either a 24-h fast ( , Munday et al., 1991 
) and dietary energy restriction ( ). However, in other studies, fasting and caloric restriction did notWitters et al., 1994 Jiang et al., 2008 
activate liver AMPK ( , ). Interestingly, it has been noted that the metabolic demands during muscularGonzalez et al., 2004 To et al., 2007 
work results in a decrease in energy status of the liver ( ). Indeed, increased AMPK activation has been demonstratedCamacho et al., 2006 
following short-term exercise in rat liver ( , ). Long-term exercise also induced significantCarlson and Winder, 1999 Park et al., 2002 
increase in AMPK phosphorylation as well as AMPK 1-and 2-subunit mRNA levels in the liver, suggesting a role for hepatic AMPK inα α
long-term exercise-induced hepatic adaptations ( ).Takekoshi et al., 2006 
In the liver, the transition from the fasted to the fed state is also associated with physiological changes in energy dynamics. The
reversal of the metabolic response to starvation includes alterations in enzyme phosphorylation states and changes in the concentration of
key regulatory molecules. It has been reported that AMPK coordinates the changes in the activity and/or expression of a number of
enzymes of lipid metabolism during refeeding ( , , , ).Munday et al., 1991 Gonzalez et al., 2004 Assifi et al., 2005 Dentin et al., 2005 
Refeeding causes a 40  decrease in the activity of AMPK 1 within 1 h, with additional decrease in both AMPK 1 and AMPK 2% α α α
activities occurring between 1 and 24 h ( ). It is noteworthy that LKB1 activity could also be modulated during theAssifi et al., 2005 
starvation-refeeding transition in association with its acetylation and intracellular localization ( ). The modification ofLan et al., 2008 
AMPK activity during the starved-fed transition is compatible with earlier studies that linked these changes to increase in plasma insulin [
reported to decrease AMPK activity in isolated hepatocytes ( ) , and decrease in glucagon showed to activateWitters and Kemp, 1992 ] [
hepatic AMPK ( ) , possibly by a protein kinase A-induced phosphorylation and activation of LKB1 (Sim and Hardie, 1988 ] Kimball et al.,
). In addition, changes in circulating levels of various hormones and adipokines during refeeding, may directly affect AMPK activity2004 
in the hepatocytes and could also contribute to the fasted-to-fed transition from catabolism to anabolism in the liver. It has been reported
that hepatic AMPK can be regulated by ghrelin ( , ), endocannabinoids ( ),Barazzoni et al., 2005 Kola et al., 2005 Kola et al., 2005 
glucocorticoids ( ), resistin ( ) and adiponectin ( ) ( ).Christ-Crain et al., 2008 Banerjee et al., 2004 Yamauchi et al., 2002 Table 1 
As well as responding to metabolic stresses, hepatic AMPK activity is modulated by various pharmacological and natural drugs
including AICAR  (5-aminoimidazole-4-carboxamide-1- -D-ribofuranoside) ( ), compound A-769662 ([ ] β Corton et al., 1995 Cool et al.,
), polyphenols ( ) and two major classes of existing antidiabetic drugs biguanides (metformin and phenformin) (2006 Zang et al., 2006 
) and thiazolidinediones (TZDs) ( ).Zhou et al., 2001 Saha et al., 2004 
AICAR is a cell-permeable nucleoside which could be metabolically converted to 5-aminoimidazole-4-carboxamide ribotide (AICA
ribotide or ZMP) by adenosine kinase. ZMP shares some structural similarities with 5 -AMP and can mimic all of the allosteric effects of 5′
-AMP on the AMPK system ( ). During the last decade, AICAR has been extensively used both and to′ Corton et al., 1995 in vitro in vivo 
activate hepatic AMPK ( ) because it was generally assumed that activation of AMPK by AICAR does not affectViollet et al., 2006 
cellular levels of AMP, ADP or ATP ( ). However, this view has been recently challenged, showing that treatment ofCorton et al., 1995 
hepatocytes with AICAR concentrations above 200 M depleted intracellular ATP levels ( , ).μ Guigas et al., 2006 Mukhtar et al., 2008 
Importantly, AMPK-independent effects of AICAR in the control of hepatic glucose uptake ( ), phosphatidylcholineGuigas et al., 2006 
synthesis ( ) and autophagic proteolysis ( ) probably associated with its effect on ATP depletion whereJacobs et al., 2007 Meley et al., 2006 
also recently reported. Detrimental effect of AICAR is likely to be due to an AMPK-independent inhibition of mitochondrial oxidative
phosphorylation induced by a concomitant effect of ZMP on the mitochondrial respiratory chain complex 1 and a drop of adenine
nucleotides and inorganic phosphate following its phosphorylation ( ). Furthermore, we established that ZTPGuigas et al., 2007 
accumulation induced uncoupling of mitochondrial oxidative phosphorylation, an effect that could worsen the change in cellular energetic
by decreasing the yield of ATP synthesis ( ). In addition, it should be noted another important caveat in the use ofGuigas et al., 2007 
AICAR because ZMP accumulation does affect certain other AMP-regulated enzymes such as glucokinase and fructose
1,6-bisphosphatase causing inhibition of glycolysis and gluconeogenesis in hepatocytes ( , ).Vincent et al., 1992 Vincent et al., 1991 
Therefore, like all pharmacological approaches, results of experiments using AICAR must be interpreted with caution and it remains to be
clearly determined whether all AICAR effects described are mediated by AMPK. In addition, it has been demonstrated that uptake of
AICAR into cells, mediated by the adenosine transport system, is blocked by a number of protein kinase inhibitors, thus preventing ZMP
accumulation and subsequent AMPK activation ( , ).Fryer et al., 2002 Guigas, unpublished results 
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Recently, a new class of AMPK activators have been identified after the screening of a chemical library using partially purified AMPK
from rat liver. The non nucleoside thienopyridone A-592017 emerged from the initial screen, and after optimization the more potent one,
A-769662, was developed. Specificity of this new compound has been tested on a panel of 76 protein kinases and the majority of kinases
were not significantly affected at 10 M ( ) suggesting that A-769662 is a new specific activator of AMPK. Unlikeμ Goransson et al., 2007 
other AMPK activators, A-769662 directly activates native AMPK complex purified from rat liver in cell-free essays by mimicking both
effects of AMP on allosteric activation and inhibition of dephosphorylation of AMPK complex ( , Goransson et al., 2007 Sanders et al.,
). However, A-769662 and AMP binding sites on AMPK complex are unlikely to be identical. Firstly, in the presence of saturating2007 
AMP concentration, A-769662 stimulated further AMPK activity ( , ). Second, A-769662Cool et al., 2006 Goransson et al., 2007 
allosterically activates AMPK complexes harboring a mutation in the 1 subunit that abolishes allosteric activation by AMP (γ Sanders et
). Interestingly, an AMPK complex lacking the glycogen binding domain of the  subunit or containing a mutation of Ser-108 toal., 2007 β
alanine (an autophosphorylation site within the glycogen binding domain of the 1 subunit) completely abolished the allosteric effect ofβ
A-769662, while only partially reducing AMP activation ( ). It has been reported that AMPK activation by A-769662Sanders et al., 2007 
was independent of the upstream kinase utilized ( , ). Importantly, neither change in adenineGoransson et al., 2007 Sanders et al., 2007 
nucleotide levels ( ) nor alterations in mitochondrial oxidative phosphorylation ( ) following treatmentCool et al., 2006 Guigas et al., 2008 
with A-769662 have been detected in hepatocytes. Addition of A-769662 to primary mouse hepatocytes stimulates AMPK activity and
phosphorylation of its known downstream targets but was completely abolished in hepatocytes lacking AMPK 1 and 2 catalytic subunitsα α
( ). Short-term treatment with this compound recapitulates many of the effects expected for an hepaticGoransson et al., 2007 in vivo 
activation of AMPK ( ) as it is mainly targeted to the liver ( ).Foretz et al., 2005 Cool et al., 2006 
Polyphenols, including resveratrol and epigallocatechin-3-gallate (EGCG), have been recently identified as potent activators for
AMPK and ( , , ). Some of the beneficial metabolic actions ofin vitro in vivo Baur et al., 2006 Collins et al., 2007 Zang et al., 2006 
polyphenols are mediated by their ability to activate sirtuin 1 (SIRT1), a mammalian ortholog of Sir2 (silent information regulator 2), an
NAD-dependent deacetylase that acts as a master metabolic sensor of NAD  and modulates cellular metabolism and life span (+ Baur et al.,
). It has been demonstrated that SIRT1 activation by resveratrol functions as an upstream regulator in the LKB1/AMPK signaling2006 
axis ( ). The ability of resveratrol to stimulate AMPK was mimicked by overexpression of SIRT1 and abolished byHou et al., 2008 
knockdown or pharmacological inhibition of SIRT1. Furthermore, AMPK activation by resveratrol-activated SIRT1 is mediated by the
upstream kinase, LKB1, but not CaMKK . The mechanism by which SIRT1 activation by polyphenols leads to LKB1-dependent AMPKβ
activation relies on the direct deacetylation of LKB1 by SIRT1 ( ). Indeed, activation of SIRT1 deacetylates LKB1, whichLan et al., 2008 
in turn increases its cytoplasmic localization, its association with the LKB1 activator STRAD and its ability to activate AMPK.
Nevertheless, it should be noted that AMPK activation by polyphenols may involve distinct regulators. It has been shown that the
EGCG-induced increase in AMPK phosphorylation is mediated by CaMKK activation through production of ROS ( ).Collins et al., 2007 
Furthermore, the SIRT1 regulation of LKB1/AMPK signaling appears to be tissue-specific as resveratrol-stimulated AMPK activation in
neurons was independent of SIRT1 ( ).Dasgupta and Milbrandt, 2007 
The molecular pathway of AMPK activation by the antidiabetic drug metformin has been unclear ( ) but the directZhou et al., 2001 
inhibition of the respiratory chain complex 1 by the biguanide constitutes the more convincing molecular mechanism, thus, leading to
reduced cellular ATP and increased AMP ( , , ). This is supported by the factEl-Mir et al., 2000 Brunmair et al., 2004 Owen et al., 2000 
that metformin treatment in primary hepatocytes resulted in a decrease in ATP content ( ). It should be noted thatGuigas et al., 2006 
metformin could also exert AMPK-independent effects in the liver, probably due to its effect on cellular ATP levels ( ).Guigas et al., 2006 
It has been reported that TZDs acutely activate AMPK by a mechanism independent of PPAR -regulated gene transcription, whichγ
appears to be associated with change in cellular energy state and could potentially increase AMPK activity ( , Brunmair et al., 2004 Saha et
).al., 2004 
Regulation of hepatic lipid metabolism
AMPK phosphorylates and inactivates a number of metabolic enzymes involved in lipid metabolism in order to maintain liver energy
status. AMPK coordinates the changes in the hepatic lipid metabolism and, so, regulates the partitioning of fatty acids between oxidative
and biosynthetic pathways. 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) and acetyl CoA carboxylase
(ACC), key enzymes in cholesterol and fatty acid synthesis respectively, were the first enzymes shown to be phosphorylated and
inactivated by AMPK ( , ). Although the action of AMPK is achieved by rapid and directCorton et al., 1994 Henin et al., 1995 
phosphorylation of these enzymes, long-term effects have also been clearly demonstrated on gene expression. AMPK activation by
AICAR or by the use of adenovirus-mediated overexpression of a constitutively active form of the 2 catalytic subunit (AMPK 2-CA)α α
inhibits glycolytic and lipogenic gene expression ( , , , , Foretz et al., 2005 Leclerc et al., 2001 Woods et al., 2000 Foretz et al., 1998 
), preserving glucose for ATP-producing pathways rather than for lipid synthesis. Of note, AMPK activation reducesLeclerc et al., 1998 
expression of sterol regulatory element-binding protein-1c (SREBP1c) ( , ) and carbohydrate responseZhou et al., 2001 Foretz et al., 2005 
element binding protein (ChREBP) ( , ), transcription factors playing a key role in the– Foretz et al., 2005 Kawaguchi et al., 2002 
transcriptional regulation of lipogenic and glycolytic genes by insulin and glucose, respectively. In addition, it has been also reported that
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AMPK directly phosphorylates ChREBP and modulates its DNA binding activity ( ). Polyunsaturated fatty acidsKawaguchi et al., 2002 
(PUFAs) are known to repress glycolytic and lipogenic gene expression and raised the question about a role of AMPK in mediating the
effect of PUFAs on gene transcription. To address this point, we investigated the effect of PUFAs in mice lacking AMPK 1/ 2 catalyticα α
subunits in the liver (AMPK 1 2 / ). In the absence of hepatic AMPK, PUFAs continue to inhibit glycolytic and lipogenic geneα α LS − −
expression indicating the existence of AMPK-independent mechanism(s) ( ).Viollet et al., 2006 
In the cholesterol synthesis pathway, AMPK blocks the conversion of HMG-CoA to mevalonate. One could expect detrimental effect
on cholesterol homeostasis when AMPK activity is altered. In total and liver-specific AMPK 2 KO mice, plasma levels for total and HDLα
cholesterol are not statistically different compared to controls but have a tendency to be higher ( , Andreelli et al., 2006 Viollet et al., 2003 
). This suggested that remaining 1 subunit activity in AMPK 2 KO mice is sufficient to control hepatic cholesterol synthesis and thatα α
HMG-CoA reductase is a target for both catalytic isoforms of AMPK.
ACC is an important rate-controlling enzyme for the synthesis of malonyl-CoA, which is both a critical precursor for biosynthesis of
fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation via the allosteric regulation of carnitine palmitoyltransferase-1
(CPT-1) which catalyzes the entry of long-chain fatty acyl-CoA into mitochondria. Inhibition of ACC by AMPK leads to a fall in
malonyl-CoA content and a subsequent decrease in fatty acid synthesis concomitantly with an increase in -oxidation ( , β Brusq et al., 2006 
). Exposure of hepatocytes to AICAR also produces a strong stimulation of long-chain fatty acid oxidation as a resultVelasco et al., 1997 
of an increase in the rate of ketogenesis and an inhibition of triacylglycerol synthesis via phosphorylation of sn-glycerol-3-phosphate
acyltransferase (GPAT) ( ). In addition, overexpression of AMPK 2-CA in the liver increases plasma ketone bodiesMuoio et al., 1999 α
levels, a surrogate marker for hepatic -oxidation ( ). Interestingly, AMPK-induced ACC phosphorylation is impaired inβ Foretz et al., 2005 
hepatocytes deleted of both catalytic subunit, contributing to increase intracellular malonyl CoA levels and triglyceride (TG) accumulation
in the liver (B. Viollet, M. Foretz, unpublished results). Thus, these results indicate that AMPK regulates cellular lipid metabolism in large
part through stimulation of fatty acid oxidation. However, recent studies showed that AMPK also stimulates a previously unrecognized
pathway that involves constitutive exocytosis of lipoproteins ( ). This alternative pathway appears to be quantitativelyPuljak et al., 2008 
important for intracellular lipid homeostasis and may function in parallel with fatty acid oxidation to regulate intracellular lipid content.
Regulation of hepatic mitochondrial biogenesis and function
As reported recently, AMPK has been also involved in the control of mitochondrial biogenesis in the liver, a role already evidenced in
skeletal muscles ( ). First evidences were brought by treatment with resveratrol, a polyphenol constituent ofReznick and Shulman, 2006 
red wine, which increases mitochondrial number in liver in association with AMPK activation ( ). Second, AMPK 1 2Baur et al., 2006 α α LS 
/  mice have reduced mitochondrial biogenesis as suggested by decreased transcript and protein expression of key mitochondrial− −
constituents such as peroxisome proliferator-activated receptor-  coactivator-1  (PGC-1 ), cytochrome c oxidase I (COX I), COX IV andγ α α
cytochrome c genes ( ) ( ). Interestingly, both mitochondrial respiration and basal level of ATP were alsoGuigas et al., 2007 Figure 1 
significantly lower in hepatocytes isolated from AMPK 1 2 /  mice compared with control mice ( ). This resultα α LS − − Guigas et al., 2006 
emphasizes the importance of AMPK in the regulation of cellular energy homeostasis via the control of adaptive mitochondrial function.
Thus, diminished AMPK activity may be an important contributing factor in the reduced mitochondrial function and dysregulated
intracellular lipid metabolism associated with hepatic insulin resistance. The exact mechanisms by which deletion of AMPK in the liver
affects PGC-1  expression and mitochondrial biogenesis remain to be elucidated but could be due to a lack of protein-protein interaction,α
as suggested in skeletal muscle ( ).Jager et al., 2007 
Regulation of hepatic glucose production
Recent results from various animal models confirm the physiological importance of hepatic AMPK for whole-body glucose
homeostasis. It has been first shown that systemic infusion of AICAR in normal and insulin-resistant obese rats leads to the inhibition of
hepatic glucose production (HGP) ( ). Then, several studies reported that AICAR treatment improve blood glucoseBergeron et al., 2001 
levels and glucose tolerance in animal models of type 2 diabetes. However, the relative roles played by skeletal muscle and liver in
mediating the hypoglycemic effect of AICAR remain unclear. In muscle-specific AMPK dominant-negative mice, AICAR has a weaker
hypoglycemic effect than in control animals ( ), suggesting that this compound lowers glycemia at least partly by increasingMu et al., 2001 
muscle glucose uptake. We demonstrated that AMPK 1 2 /  mice display an impaired hypoglycemic response to AICAR, indicatingα α LS − −
that the liver as well participate to the hypoglycemic effect of AICAR ( ). It has been also reported that short-term hepaticFigure 2 
expression of AMPK-CA leads to mild hypoglycemia in normal mice ( , ) and abolishesForetz et al., 2005 Viana et al., 2006 
hyperglycemia in diabetic and STZ-induced diabetic mice ( ). The hypoglycemic effect of AMPK activation isob/ob Foretz et al., 2005 
consistent with the abolition of HGP, as suggested by the down-regulation of gluconeogenic gene expression (e.g., phosphoenolpyruvate
carboxykinase PEPCK  and glucose-6-phosphatase G6Pase ) and inhibition of glucose production in hepatic cells expressing AMPK-CA[ ] [ ]
or treated with AICAR ( , , ). Using transcriptional profiling of hepatocyte cellLochhead et al., 2000 Foretz et al., 2005 Viana et al., 2006 
lines treated with AICAR, the dual specificity phosphatase Dusp4 and the immediate early transcription factor Egr1 have been identified
as transcriptional targets of AMPK that are necessary for its ability to fully repress glucose production ( ). Egr1 andBerasi et al., 2006 
AMPK in the liver
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Dusp4 act sequentially to mediate the inhibitory effect of AMPK on hepatic gluconeogenesis: increase in Egr1 protein is accompanied
with increased binding to the Dusp4 promoter leading to Dusp4 expression and inhibition of PEPCK and G6Pase gene transcription (
).Berasi et al., 2006 
The importance of AMPK in the control of glucose output by the liver was recently highlighted by the potent effects of circulating
adipocyte-derived hormones on whole-body glucose metabolism. A physiological link has been established between circulating resistin
levels and hepatic AMPK activity in the maintenance of blood glucose ( ). Low blood glucose levels and reducedBanerjee et al., 2004 
HGP in mice lacking resistin are likely related, at least in part, to activation of AMPK and decreased expression of gluconeogenic enzymes
in the liver. Interestingly, adiponectin signaling opposes that of resistin in the control of glucose homeostasis and activation of AMPK is
though to underlie the ability of this adipocyte hormone to reduce HGP ( ). According to this result, adiponectinYamauchi et al., 2002 
failed to regulate HGP in liver-specific AMPK 2 KO mice ( ). AdipoR1 and AdipoR2 serve as adiponectin receptorsα Andreelli et al., 2006 
and functional differences in adiponectin-signaling pathways in the liver have been recently demonstrated with AdipoR1 being tightly
linked to activation of AMPK pathways whereas AdipoR2 being more associated with the activation of peroxisome proliferator-activated
receptor-  (PPAR- ) pathways ( , ).α α Yamauchi et al., 2007 Bjursell et al., 2007 
Recently, the transcriptional co-activator transducer of regulated CREB activity 2 (TORC2) has been identified as a pivotal component
of the gluconeogenic program ( ). TORC2 mediates CREB-dependent transcription of PGC1  and its subsequentKoo et al., 2005 α
gluconeogenic targets PEPCK and G6Pase. TORC2 is regulated by multiple signaling pathways in response to changes in glucagon and
insulin levels or intracellular energy status. Phosphorylation on Ser171 confers binding of the protein 14-3-3 and sequestration of TORC2
out of the nucleus, resulting in inhibition of gluconeogenic gene expression. The kinase responsible for phosphorylating Ser171 of TORC2
was initially identified as salt-inducible kinase 2 (SIK2), an AMPK-related protein kinase ( ). Recently, activation ofScreaton et al., 2004 
AMPK was also found to phosphorylate TORC2 and regulate cytoplasmic translocation of TORC2 in primary hepatocyte cultures (Koo et
). Interestingly, in the absence of LKB1 in the liver, the expression of some of the key gluconeogenic genes are enhanced and theal., 2005 
antidiabetic drug metformin no longer reduced blood glucose levels, demonstrating that hepatic LKB1/AMPK axis is required to maintain
blood glucose levels ( ). LKB1 phosphorylates and activates a number of kinases including AMPK and SIK familyShaw et al., 2005 
members ( ), suggesting that genetic deletion of LKB1 in liver will result in the loss of multiple metabolic checkpointsLizcano et al., 2004 
in the regulation of TORC2. In LKB1-deficient liver, AMPK was almost completely inactive, TORC2 was predominantly nuclear and
fasting blood glucose levels were highly increased concomitantly with PEPCK and G6Pase gene expression ( ). TheShaw et al., 2005 
reduction of TORC2 protein levels by injection of adenoviruses bearing small hairpin RNA for TORC2 in mice lacking LKB1 in the liver
resulted in decreased PGC-1  protein levels accompanied by a significant decrease in fasting blood glucose levels, suggesting that TORC2α
is a critical downstream target of LKB1-dependent kinases in the control of gluconeogenesis ( ). In addition, a recentShaw et al., 2005 
study has shown that metformin regulates hepatic gluconeogenesis through AMPK-dependent regulation of the orphan nuclear receptor
small heterodimer partner (SHP) ( ). AMPK activation caused upregulation of SHP gene expression and this in turn,Kim et al., 2008 
inhibits PEPCK and G6Pase gene expression. It has been proposed that metformin could regulate the expression of hepatic gluconeogenic
genes via both a short-term pathways, involving the protein stabilization or phosphorylation of AMPK-targeted transcription factors and
coactivators, such as TORC2 ( ), HNF4  ( , ) and FoxO1 ( ) and aShaw et al., 2005 α Leclerc et al., 2001 Hong et al., 2003 Barthel et al., 2002 
long-term effect exerted via the induction of SHP gene expression ( ) ( ). Lastly, it should be noted that AMPK hasKim et al., 2008 Figure 3 
been also involved in the repression of gluconeogenic genes in response to ECGC treatment via a LKB1-independent pathway relying on
CaMKK activation through production of ROS ( ).Collins et al., 2007 
Management of glucose homeostasis and dyslipidemia
The growing evidence that AMPK regulates the coordination of anabolic and catabolic metabolic processes represents an attractive
therapeutic target for intervention in many conditions of disordered energy balance, including obesity, type 2 diabetes, and the metabolic
syndrome ( ). Support for this idea came from treatment with AICAR of various animal models of insulinWinder and Hardie, 1999 in vivo 
resistance, causing improvement of metabolic disturbances, at least partly by lowering blood glucose levels and increasing insulin
sensitivity ( , , , , , ).Bergeron et al., 2001 Buhl et al., 2002 Iglesias et al., 2002 Song et al., 2002 Pold et al., 2005 Fiedler et al., 2001 
Chronic treatment with AICAR was also shown to reduce plasma TG levels and adiposity in obese animals ( , Bergeron et al., 2001 Buhl et
, ). Furthermore, similar beneficial metabolic effects have been also obtained by direct AMPK activation in theal., 2002 Song et al., 2002 
liver by overexpression of AMPK-CA or by the use of the AMPK activator A-769662, leading to decreased plasma glucose, plasma TG
levels and adiposity in diabetic, obese and high fat fed mice ( , , ). These resultsCool et al., 2006 Foretz et al., 2005 Yang et al., 2008 
suggest that direct targeting of the liver is crucial for improving glucose and lipid metabolism, thereby preventing and treating type 2
diabetes. Accordingly, it appears that the major effect of intravenous AICAR infusion in type 2 diabetic patients was on the liver with
inhibition of hepatic glucose output and decreased blood glucose levels ( ). However, as liver samples were not collectedBoon et al., 2008 
in this study, one can only speculate on the role of hepatic AMPK in this therapeutic effect of AICAR. Indeed, inhibition of hepatic
glucose output could have resulted from AMPK-independent effects, such as inhibition of fructose-1,6-bisphosphatase by ZMP
accumulation in the liver ( ) and see above  Furthermore, AICAR administration could also stimulate hepatic fatty acid[ Vincent et al., 1991 ]
oxidation and/or inhibit whole body lipolysis, thereby reducing plasma non-esterified fatty acids (NEFA) concentration (Boon et al., 2008 
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). Unexpectedly, the effect of AICAR infusion on skeletal muscle glucose uptake was not evident and no changes in AMPK activity were
detected in skeletal muscle. Similarly, in another study performed in healthy humans, AMPK activity was not modified in skeletal muscle
after AICAR infusion ( ),reinforcing the role of the liver in the action of AICAR.Cuthbertson et al., 2007 
Several reports indicate that metformin and TZDs can reduce risk for type 2 diabetes in people with glucose intolerance (Knowler et
). Interestingly, these two drugs have been reported to activate AMPK which is now considered as a new target for theal., 2002 
management of insulin-resistant state. Consistent with these data, AMPK now appears to be activated by a multitude of natural products
such as polyphenols and traditional Chinese medicine able to reduce blood glucose levels in obese and diabetic animal models ( ).table 1 
Pathophysiology and management of type 2 diabetes are complex. Increased concentrations of NEFA and inflammatory cytokines (e.g.,
tumor necrosis factor  TNF  and interleukin 6 IL-6 ) released by expanded visceral adipose tissue are crucial mechanisms involved inα [ α] [ ]
the alteration of insulin signaling cascade ( ). Adiponectin is another important key of the pathophysiology of type 2Stumvoll et al., 2005 
diabetes. Adiponectin has favourable effects on insulin resistance, hepatic steatosis and inflammation ( ). It is nowKadowaki et al., 2006 
well established that circulating levels of adiponectin are decreased in individuals with obesity and insulin resistance, suggesting that its
deficiency may have a causal role in the etiopathogenesis of these diseases and their consequences. Thus, adiponectin replacement or
restoration of endogenous secretion in humans may represent a promising approach to prevent and/or treat obesity, insulin resistance and
the metabolic syndrome. The chronic effects of adiponectin on insulin resistance were investigated by generating adiponectinin vivo 
transgenic mice. Globular adiponectin transgenic mice showed partial amelioration of insulin resistance and diabetes (ob/ob Yamauchi et
) and full length adiponectin showed suppression of insulin-mediated endogenous glucose production ( ).al., 2003 Yamauchi et al., 2002 
Interestingly, it has been shown that metabolic and insulin-sensitizing effects of TZDs are in part mediated through increase in adiponectin
availability. Indeed, TZDs metabolic effects are abolished in lipoatrophic mice suggesting that adipose tissue is an essential key of TZDs
action ( ). In addition, TZDs can markedly enhance the expression and secretion of adiponectin and Chao et al., 2000 in vitro in vivo 
through the activation of its promoter and also by blocking the suppressive effect of TNF  on the production of adiponectin. Even if theα
intracellular adiponectin signaling is not yet completely described, it is clearly demonstrated that adiponectin activates hepatic AMPK (
). In consequence, TZDs probably activate AMPK by an indirect mechanism, through increase of adiponectin levels.Yamauchi et al., 2002 
This is suggested by the reduction of AMPK activation by rosiglitazone in adiponectin KO mice ( ). A possibleNawrocki et al., 2006 
similar mechanism of action could concern AICAR (but not metformin) which increase the expression of adiponectin in human adipose
tissue as TZDs ( ).Lihn et al., 2004 
Management of fatty liver and hepatic fibrosis
Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease in western countries, is considered as the hepatic
manifestation of the metabolic syndrome ( ). NAFLD is highly associated with obesity and insulin resistance and represent aAngulo, 2002 
broad spectrum of liver abnormalities ranging from simple hepatic steatosis (accumulation of TG inside hepatocytes) to a more severe
form, nonalcoholic steatohepatitis (NASH), which is associated with hepatocyte damage, chronic inflammation, and fibrosis, and may
progress to cirrhosis and liver failure. Studies in humans and various animal models have suggested that efforts to enhance insulin
sensitivity might improve fatty liver disease, a situation frequently observed in patients with metabolic syndrome. The efficacy of
metformin as a treatment for fatty liver disease has been confirmed in obese, mice, which develop hyperinsulinemia, insulinob/ob 
resistance and fatty livers ( ). Recent studies suggest that activation of AMPK accounts for the lipid-lowering effect ofLin et al., 2000 
metformin in cultured hepatocytes ( ). Similarly, adiponectin restores insulin sensitivity and decreases hepatic steatosis byZang et al., 2004 
lowering TG content in the liver of obese mice ( , ). The action of adiponectin is linked to anXu et al., 2003 Yamauchi et al., 2001 
activation of hepatic AMPK, ultimately leading to decreased fatty acid biosynthesis and increased mitochondrial fatty acid oxidation (
). The role of AMPK has been confirmed by the decrease in liver TG content in lean and obese rodents duringYamauchi et al., 2002 
AICAR infusion ( ) and treatment with direct AMPK activator A-769662 ( ). In addition, it has beenBergeron et al., 2001 Cool et al., 2006 
recently demonstrated that resveratrol improves insulin sensitivity and protects against lipid accumulation in the liver of diabetic and
high-fat fed animals concomitantly with activation of hepatic AMPK ( , ). These effects have beenBaur et al., 2006 Shang et al., 2008 
correlated to increased mitochondrial number and SIRT1-mediated PCG-1  deacetylation, and decreased expression of lipogenic genes inα
the liver. Similarly, the beneficial effect of betaine (trimethylglycine), a naturally occurring metabolite of choline, on high-sucrose
diet-induced hepatic steatosis in mice is associated with increased activation of hepatic AMPK ( ). Promising therapeuticSong et al., 2007 
effects of betaine supplementation on human NAFLD have been reported in a pilot clinical studies ( ) but the useAbdelmalek et al., 2001 
of betaine has been also described earlier in the treatment of alcoholic fatty liver disease (AFLD) ( ). Although, theBarak et al., 1997 
underlying causes of NAFLD and AFLD are clearly different, there are similarities in the disturbances of hepatic metabolism. This is
supported by reports showing that treatement with adiponectin alleviated alcoholic and non-alcoholic fatty liver disease in mice, partly due
to enhanced hepatic fatty acid oxidation and decreased fatty acid synthesis ( ). Interestingly, chronic ethanol ingestionXu et al., 2003 
causes the impairment of AMPK-mediated regulation of fatty acid metabolism and may have an important role in the development of
alcoholic fatty liver ( , ). Activation of AMPK by AICAR or metformin largely blocked theYou et al., 2004 Garcia-Villafranca et al., 2008 
ability of ethanol to increase levels of SREBP1c protein and expression of SREBP1c-regulated lipogenic enzymes and also appears to
protect the liver from fatty changes associated with chronic alcohol use ( , ). Very recently, treatmentYou et al., 2004 Tomita et al., 2005 
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with resveratrol has been also shown to prevent the development of alcoholic liver steatosis through the SIRT1-AMPK signaling system
associated with increased circulating adiponectin levels and enhanced expression of hepatic AdipoR1 and R2 receptors (Ajmo et al., 2008 
).
It is now established that hepatic stellate cells (HSCs) play a crucial role in the fibrotic response during the progression of NASH (
, ). Stimuli such as liver injury activate and transdifferentiate HSCs from vitamin A-storingBataller and Brenner, 2005 Friedman, 2004 
pericytes to myofibroblast-like cells. Once activated, human HSCs become proliferative, proinflammatory and profibrogenic through
increased responsiveness to several soluble mediators ( ). Despite the clear role of insulin resistance in the progression ofFriedman, 2004 
fibrosis, the molecular mechanisms involved in these conditions are still unclear. Adiponectin levels which have been directly correlated
with insulin sensitivity are closely and inversely associated with degree of hepatic steatosis, necroinflammation, and fibrosis in NAFLD (
). Recent studies have demonstrated that in rat HSCs, adiponectin inhibits proliferation, migration, and expression ofTargher et al., 2006 
fibrogenic genes, and it may induce apoptosis of activated cells ( ). Furthermore, administration of adiponectinDing et al., 2005 in vivo 
prevents proliferation of activated HSCs and reduces the development of fibrosis and liver damage during experimental steatohepatitis (Xu
, ). In addition to adiponectin, AICAR and metformin significantly inhibited proliferation and migration ofet al., 2003 Kamada et al., 2003 
human HSCs in a dose-dependent manner ( ). The beneficial effect of these compounds is linked to suppression ofCaligiuri et al., 2008 
platelet-derived growth factor (PDGF) expression in HSCs and subsequent inhibition of type I procollagen secretion (Caligiuri et al., 2008 
, ). Activation of AMPK by adiponectin plays a pivotal role in this molecular pathway since the dose-dependentAdachi and Brenner, 2008 
PDGF suppression is abrogated in the presence of dominant-negative AMPK ( ) or by the knock-down ofAdachi and Brenner, 2008 
AMPK ( ). Additional mechanisms, such as short-term inhibition of PDGF-mediated phosphorylation of ribosomal S6Caligiuri et al., 2008 
kinase (p70S6K) and 4E binding protein-1 (4EBP1) (downstream effectors of the mammalian target of rapamycin complex 1 (mTORC1)
pathway) by AICAR have been demonstrated ( ). AICAR and metformin could also inhibit HSCs proliferation viaCaligiuri et al., 2008 
suppression of ROS production and subsequent inhibition of AKT pathway ( ). Taken together, data from recentAdachi and Brenner, 2008 
studies provide evidence that AMPK and adiponectin inhibit HSCs proliferation and hepatic fibrosis via multiple molecular mechanisms
and suggest that use of drugs activating hepatic AMPK may have an additional rationale in their antifibrogenic properties.
Conclusion
Hepatic metabolism is highly sensitive to the variations in nutritional and hormonal signals reflecting changes in whole body energy
demands. The AMPK system plays a major role in the regulation of hepatic glucose and lipid metabolism through its acute effect on
energy metabolism and long-term effects on gene expression pattern in the liver. Activation of hepatic AMPK causes a switch from
anabolic to catabolic state and entails metabolic consequences that are beneficial for diabetic patients, such as inhibition of HGP and
restoration of blood glucose levels. AMPK is a key player in regulating energy balance at both cellular and whole-body levels, placing it as
an ideal therapeutic target for the treatment of altered energy metabolism that occur in conditions like insulin resistance, type 2 diabetes
and the metabolic syndrome. A large number of AMPK activators have been employed with promising results in animal models with
obesity or type 2 diabetes and also in preliminary studies with diabetic patients. These encouraging results have provided the rationale for
the development of new pharmacological but also nutritional AMPK activators. However, the widespread cellular functions of AMPK
make its selective targeting in therapeutics a difficult one, with simultaneous advantageous and deleterious consequences being possible.
One of the major caveats in the use of AMPK activators is their possible role in the regulation of food intake. Stimulation of AMPK
expressed in specific nuclei of the hypothalamus has been shown to increase food intake ( ). The ideal AMPKMinokoshi et al., 2004 
activators will be administrated by the oral route, will activate AMPK at low concentration and be effective in specific target tissue, such
as the liver but not the hypothalamus, and will also have minimal off-target and/or side effects. Finally, it is now becoming apparent that
distinct expression patterns of AMPK isoforms exist between rodent and human liver. This finding will have significant implications for
the understanding of the physiological role of AMPK complexes across species and for the design of new therapeutic agents targeting
human AMPK complexes.
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Figure 1
Alterations in mitochondrial biogenesis in hepatocytes from AMPK 1 2 /  miceα α LS − −
Hepatocytes from wild-type (black bars) or AMPK 1 2 /  mice (open bars) were isolated and AMPK 1 and 2 activities, oxygen(A) α α LS − − α α
consumption rate ( O ), intracellular ATP concentrations, cytochrome c (Cyt. C) and cytochrome oxidase (COX IV) contents, and citrateJ 2 
synthase activity (CS) were measured. In separate experiments, RNA was extracted from freeze-clamped livers of wild-type (black bars)(B) 
and AMPK 1 2 /  (open bars) mice starved for 24h and quantitative real-time PCR was performed on cDNA. The mRNA contents for theα α LS − −
indicated gene were normalized for -actin and expressed relative to that in wild-type mice. The results of all experiments indicating thatβ (C) 
AMPK is an important regulator of mitochondrial biogenesis in the liver are summarized in a simplified scheme. Deletion of AMPK •
subunits in hepatocytes leads to reduced mitochondrial biogenesis as suggested by decreased transcript and protein expression of key
mitochondrial constituents such as peroxisome proliferator-activated receptor-  coactivator-1  (PGC-1 ) and mitochondrial transcriptionγ α α
factor A (Tfam) which control the expression of nuclear and mitochondrial genes involved in mitochondrial oxidative phosphorylation
(OXPHOS). Accordingly, mitochondrial respiration and basal level of ATP were significantly decreased. These data emphasize the
importance of AMPK in the control of adaptive mitochondrial function. p<0.05 compared with wild-type mice.*
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Figure 2
The hypoglycemic effect of AICAR is dependent partially on hepatic AMPK
AMPK 1 2 /  mice deleted for both AMPK catalytic subunit in the liver are resistant to hypoglycemic effect of AICAR. AICAR toleranceα α LS − −
test was performed on overnight fasted AMPK 1 2 /  mice injected intraperitonealy with AICAR at 0.12 g/kg and 0.25 g/kg and tailα α LS − −
blood was collected at 0, 20, 40, 60 and 80 min for determination of glucose concentration using a glucometer. p<0.005, p<0.001, * ** ***
p<0.0001 vs control mice by unpaired, two-tailed Student t test.
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Figure 3
AMPK controls gluconeogenic gene expression by promoting TORC2 phosphorylation
In response to fasting, glucagon promotes dephosphorylation of TORC2 on Ser171 through the PKA-dependent inhibition of SIK, leading(A) 
to its nuclear translocation and association with CREB transcription factor, driving the expression of the PGC1  co-activator. Expression ofα
the coactivator PGC-1  drives the transcription of key gluconeogenic enzymes such as PEPCK and G6Pase in association with theα
transcription factor HNF4a and the forkhead family activator FoxO1. Phosphorylation of TORC2 (Ser171) is controlled by insulin(B) 
through AKT2-dependent activation of SIK2 and by AMPK. Phosphorylated TORC2 is sequestered in the cytoplasm via a
phosphorylation-dependent interaction with 14-3-3 proteins and degraded by 26S proteasome to inhibit gluconeogenic program. The
antidiabetic drug metformin inhibits gluconeogenic gene expression through the LKB1/AMPK/TORC2 axis. TORC2 represents a central
point in the control of hepatic gluconeogenesis that senses both hormone and energy status. AMPK activation also caused upregulation of
SHP gene expression and this in turn, inhibits PEPCK and G6Pase gene expression.
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Table 1
Pharmacological and natural modulators of AMPK activity in the liver
Molecule/Compound References
Activation A-769662 ( )Goransson et al., 2007 
AICAR ( )Corton et al., 1995 
Metformin ( )Zhou et al., 2001 
Thiazolidinediones ( , )Fryer et al., 2002 Saha et al., 2004 
Adiponectin ( )Yamauchi et al., 2002 
Glucocorticoids ( )Christ-Crain et al., 2008 
Betaine ( )Song et al., 2007 
Berberine ( )Lee et al., 2006 
Bitter melon ( )Tan et al., 2008 
Combretastatin A4 ( )Zhang et al., 2008 
EGCG (epigallocatechin gallate) ( )Collins et al., 2007 
Galegine ( )Mooney et al., 2008 
Ginseng ( )Park et al., 2008 
Resveratrol ( )Zang et al., 2006 
Oltipraz ( )Bae et al., 2007 
Inhibition Ghrelin ( , )Barazzoni et al., 2005 Kola et al., 2005 
Endocannabinoids ( )Kola et al., 2005 
Resistin ( )Banerjee et al., 2004 
